Urokinase-type plasminogen activator and malignancy

Fibrinolysis and Proteolysis

Volumn 7, Issue 5, 1993, Pages 295-302

  Duffy, M J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

FIBRINOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; REVIEW;

EID: 0027385945     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-9499(93)90144-K     Document Type: Review

References (80)

1. The plasminogen activator/plasmin system
2. Biochemical and biological aspects of the plasminogen activator system
3. The human urokinase-plasminogen activator gene and its promoter
4. Tumor associated proteases
5. Plasminogen activators tissue degradation and cancer
6. Growth factors in the regulation of pericellular proteolysis
7. Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cell lines
8. Plasminogen activators in human breast cancer cell lines hormonal regulation and properties
9. Rapid elevation of plasminogen activator activity in rat tissues by prolactin
10. The control of the synthesis and secretion of plasminogen activator by rat sertoli cells in culture
11. Hormonal control of total plasminogen activator is specific to malignant DMBA-induced rat mammary tumors
12. Plasminogen activator inhibitors: hormonally regulated serpins
13. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta
14. Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colonic carcinoma cell line
15. Examination of the effects of epidermal growth factor on the production of urokinase and the expression of plasminogen activator receptor in a human colon carcinoma cell line
16. Transforming growth factor-beta induction of type 1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase
17. Transforming growth factor-beta stimulates urokinase-type plasminogen activator and DNA synthesis, but not prostaglandin E2 production, in human synovial fibroblasts
18. Basic fibroblastic growth factor induces angiogenesis in vitro
19. Hepacoyte growth factor increases urokinasetype plasminogen activator (u-PA) and u-PA receptor in Madin-Darby canine epithelial cells
20. Down regulation of epidermal growth factor correlates with plasminogen activator activity in human A431 epidermoid carcinoma cells
21. Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta
22. Transforming growth factor-beta 1 modulate basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro
23. IFN-gamma, tumor necrosis factor-alpha and urokinase regulate the expression of urokinase receptors on human monocytes
24. Regulation of urokinase receptors in monocyte-like U937 cells by phorbol myristate acetate
25. Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters
26. Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells
27. Induction of urokinase activity and malignant potential in bladder carcinoma cells after transfection of the activated Ha-ras oncogene
28. Differential modulation of urokinase-type plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases
29. Fibrinolytic properties of single chain urokinase-type plasminogen activator (prourokinase)
30. A cellular binding site for the Mr 55000 form of the human plasminogen activator, urokinase
31. The urokinase receptor and the regulation of cell surface plasminogen activation
32. Plasminogen activators in the mediation of pericellular proteolysis
33. Plasminogen activation initiated by single chain urokinase-type plasminogen activator. Potentiation by U937 monocytes
34. Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding
35. Interaction of the urokinase-type plasminogen activator with its cellular receptor induces tyrosine phosphorylation
36. The placental type plasminogen activator inhibitor PAI-2
37. Type-1 plasminogen activator inhibitor in human breast carcinoma
38. Clinical relevance of the urokinase-type plasminogen activators and their type 1 inhibitor in breast cancer
39. Inhibition of receptor-bound urokinase by plasminogenactivator inhibitors
40. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture
41. Plasminogen activators and cancer
42. Purification and characterization of the plasminogen activator secreted by human melanoma cell lines in vitro
43. Plasminogen activators in human malignant melanomas
44. Plasminogen activator activity composition in human breast cancer
45. Multiple forms of plasminogen activator in breast cancer
46. The urokinase-type plasminogen activator (u-PA) is a potent predictor of early relapse in breast cancer
47. Urokinase-the enzyme responsible for invasion and metastasis in human breast carcinoma?
48. Characterization of plasminogen activators from normal human breast and colon carcinomas
49. Plasminogen activators in human colorectal neoplasms
50. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining
51. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder
52. Increase of urokinase-type plasminogen activator gene expression in human lung and breast cancer
53. Transcriptional and post-transcriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells
54. Urokinase plasminogen activator in breast cancer: assay by both catalytic and immunoassay
55. Urokinase-type plasminogen activator a new and independent prognostic marker in breast cancer
56. Immunocytochemmical localisation of urokinase-type plasminogen activator in Lewis lung carcinoma
57. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma
58. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
59. Plasminogen activator secretion of human tumors in short term organ culture, including a comparison of primary and metastatic colon tumors
60. Urokinase plasminogen activator a significant and independent prognostic marker in breast cancer
61. Immunolocalisation of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum
62. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma
63. Localisation of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans
64. Differential protease expression by cutaneous squamous and basal cell carcinomas
65. Stromal expression of the 72kDa type IV collagenase (MMP-2) and TIMP-2 mRNA in colorectal neoplasia
66. Human plasma fibronectin as a substrate for human urokinase
67. Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase
68. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase
69. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation
70. Role of urokinase receptorin facilitating matrix invasion by cultured colon cancer cells
71. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell line A549 and Calu-1
72. Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion
73. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras transformed NIH 3T3 cells
74. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior
75. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
76. Multiparametric prognostic evaluation of biological factors in primary breast cancer
77. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients
78. The content of urinokinase-type plasminogen activator as a prognostic factor in urinary bladder cancer
79. Prognostic relevance of mucosal plasminogen activator levels in colorectal cancer